Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AMLX 
Amylyx Pharmaceuticals Inc (AMLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: AMLX (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.11
1 Year Target Price $20.11
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.24% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.35B USD | Price to earnings Ratio - | 1Y Target Price 20.11 |
Price to earnings Ratio - | 1Y Target Price 20.11 | ||
Volume (30-day avg) 7 | Beta -0.33 | 52 Weeks Range 2.60 - 16.96 | Updated Date 11/9/2025 |
52 Weeks Range 2.60 - 16.96 | Updated Date 11/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.4582 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) 23660.15% |
Management Effectiveness
Return on Assets (TTM) -32.06% | Return on Equity (TTM) -56.53% |
Valuation
Trailing PE - | Forward PE 2.77 | Enterprise Value 1242746171 | Price to Sales(TTM) 4.44 |
Enterprise Value 1242746171 | Price to Sales(TTM) 4.44 | ||
Enterprise Value to Revenue 6446.63 | Enterprise Value to EBITDA -11.71 | Shares Outstanding 109819569 | Shares Floating 73001460 |
Shares Outstanding 109819569 | Shares Floating 73001460 | ||
Percent Insiders 7.62 | Percent Institutions 85.39 |
Upturn AI SWOT
Amylyx Pharmaceuticals Inc
Company Overview
History and Background
Amylyx Pharmaceuticals was founded in 2013 by Joshua Cohen and Justin Klee, former Brown University classmates. It focuses on developing new treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its initial focus was on developing AMX0035 (Relyvrio), which received FDA approval in 2022.
Core Business Areas
- Neurological Disease Treatment: Development and commercialization of therapies for neurodegenerative diseases, primarily ALS. Focused on Relyvrio, its lead product, and future research in this area.
Leadership and Structure
Joshua Cohen and Justin Klee serve as Co-CEOs. The company has a typical biotech structure with departments for research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Relyvrio (AMX0035): An oral fixed-dose combination of sodium phenylbutyrate and taurursodiol approved for the treatment of ALS. Market share is growing but not yet established. Competitors include riluzole (Rilutek), edaravone (Radicava), and treatments from Biogen (Tofersen).
Market Dynamics
Industry Overview
The neurodegenerative disease treatment market is large and growing, driven by an aging population and increasing prevalence of diseases like ALS and Alzheimer's. It is characterized by high unmet needs and intense competition.
Positioning
Amylyx is positioned as a key player in the ALS treatment landscape, particularly after the FDA approval of Relyvrio. Its competitive advantage lies in its novel therapeutic approach and the demonstrated efficacy of Relyvrio in clinical trials.
Total Addressable Market (TAM)
The ALS treatment market is estimated at several billion USD annually. Amylyx is positioned to capture a significant share, contingent on continued positive clinical data and successful commercialization efforts.
Upturn SWOT Analysis
Strengths
- FDA approval of Relyvrio
- Novel therapeutic approach
- Strong founding team
- Dedicated focus on ALS
Weaknesses
- Reliance on a single product (Relyvrio)
- Relatively small size compared to established pharmaceutical companies
- High R&D expenses inherent in drug development
- Ongoing debate about clinical trial efficacy.
Opportunities
- Expansion to other neurodegenerative diseases
- Development of new therapies for ALS
- Strategic partnerships with larger pharmaceutical companies
- Geographic expansion to other markets
Threats
- Competition from existing and emerging ALS treatments
- Regulatory hurdles
- Patent challenges
- Negative clinical trial results for Relyvrio or other pipeline candidates
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BIIB
- ITCI
- ABBV
Competitive Landscape
Amylyx faces competition from established players with more resources. Its advantage lies in its novel therapeutic approach and focus on ALS, but it needs to continue to prove the efficacy of Relyvrio and expand its pipeline to maintain a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recent commercial launch of Relyvrio.
Future Projections: Future growth is dependent on the sales and adoption of Relyvrio, expansion of the pipeline, and potential acquisitions.
Recent Initiatives: Recent initiatives include the commercial rollout of Relyvrio, ongoing clinical trials, and exploration of new research areas.
Summary
Amylyx is a promising biotech firm that got its ALS drug approved, and its long-term success relies on proving its drug's effectiveness through trials and expanding its range of treatments. A potential concern is the debate on Relyvrio's data and the need for more therapies to maintain competitiveness as the competitive market intensifies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amylyx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-01-07 | Co-Founder, Co-CEO & Director Mr. Joshua B. Cohen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://amylyx.com |
Full time employees 123 | Website https://amylyx.com | ||
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.